0.00Open0.00Pre Close0 Volume0 Open Interest1.00Strike Price0.00Turnover0.00%IV-28.57%PremiumDec 20, 2024Expiry Date0.40Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Rani Therapeutics Stock Discussion
Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist
No comment yet